Tumor necrosis factor- are resistant to skin carcinogenesis. Nat Med. 1999;five(7):82831. 38. Popivanova BK, et al. Blocking TNF- in mice reduces colorectal carcinogenesis linked to chronic colitis. J Clin Invest. 2008;118(2):56070. 39. Egberts JH, et al. Anti-tumor necrosis issue therapy inhibits pancreatic tumor development and metastasis. Cancer Res. 2008;68(5):1443450. 40. Li J, et al. TNF- induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest. 2007;117(11):3283295. 41. Hoang T, Levy B, Ouetto N, Hainan A, RodriguezCimadevilla JC. Tumor necrosis aspect stimulates the growth on the clonogenic cells of acute myeloblastic leukemia in synergy with granulocyte-macrophage colonystimulating aspect. J Exp Med. 1989;170(1):156. 42. Khoury E, et al. Tumor necrosis factor alpha (TNF ) downregulates c-kit proto-oncogene item expression in regular and acute myeloid leukemia CD34 + cells by way of p55 TNF alpha receptors. Blood. 1994;84(8):2506514. 43. Zhang B, et al. Altered microenvironmental regulation of leukemic and typical stem cells in chronic myelogenous leukemia. Cancer Cell. 2012; 21(4):57792. 44. Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B, Deeg HJ. NF-B and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplasticsyndromes (MDSs). Blood. 2005;106(12):3917925. 45. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;five(5):41721. 46. Chen L, Madura K. Improved proteasome activity,February 2014nolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. 2007;110(13):4427435. 18. Jenkins C, et al. Nuclear factor-B as a prospective therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol. 2008;143(five):66171. 19. Jin Y, et al. Antineoplastic mechanism of niclosamide in acute myelogenous leukemia stem cells: inactivation with the NF-B pathway and generation of reactive oxygen species. Cancer Res. 2010;70(6):2516527. 20. Takahashi S, et al. Over-expression of Flt3 induces NF-B pathway and increases the expression of IL-6. Leuk Res. 2005;29(eight):89399. 21. Liu S, et al. Sp1/NFB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell. 2010;17(four):33347. 22. Nakagawa M, et al. AML1/RUNX1 functions as a cytoplasmic attenuator of NF-B signaling in the repression of myeloid tumors. Blood. 2011; 118(25):6626637. 23. Eppert K, et al. Stem cell gene expression applications influence clinical outcome in human leukemia. Nat Med. 2011;17(9):1086093. 24. Sarry JE, et al. Human acute myelogenous leukemia stem cells are rare and heterogenous when assayed in NOD/SCID/IL2Rc-deficient mice.EN4 J Clin Invest.G150 2011;121(1):38495. 25. Liu T, et al. Functional characterization of meningioma 1 as collaborating oncogene in acute leukemia.PMID:23664186 Leukemia. 2010;24(3):60112. 26. Kvinlaug BT, et al. Frequent and overlapping oncogenic pathways contribute towards the evolution of acute myeloid leukemias. Cancer Res. 2011; 71(12):4117129. 27. Neering SJ, et al. Leukemia stem cells within a genetically defined murine model of blast-crisis CML. Blood. 2007;110(7):2578585. 28. Wang Y, et al. The Wnt/-catenin pathway is essential for the development ofleukemia stem cells in AML. Science. 2010;327(5973):1650653. 29. Hinz M, et al. Nuclear aspect B-dependent gene expression profiling of Hodgkin’s illness tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activ.